| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $95M | ||
| $91M |
Buys | $0 | 0 | 0 |
Sells | $0 | 2 | 100 |
| Mitrany Rayten Michal Ety | director | 0 | $0 | 2 | $0 | $0 |
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
Over the last 12 months, insiders at BrainsWay Ltd. have bought $0 and sold $0 worth of BrainsWay Ltd. stock.
On average, over the past 5 years, insiders at BrainsWay Ltd. have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-05-26 | Sale | Mitrany Rayten Michal Ety | director | 7,980 – | $0 | $0 | -6.55% | |
| 2026-05-25 | Sale | Mitrany Rayten Michal Ety | director | 10,000 – | $0 | $0 | -2.04% |
| Increased Positions | 24 | +48.98% | 957,433 | +17.58% |
| Decreased Positions | 21 | -42.86% | 457,715 | -8.4% |
| New Positions | 7 | New | 201,734 | New |
| Sold Out Positions | 8 | Sold Out | 226,778 | Sold Out |
| Total Postitions | 52 | +6.12% | 6M | +9.17% |